March 29, 2022 7:49am
A very weak Monday evening aftermarket potentially identifies an indication
Pre-open indications: 2 SELLs, 2 BUY and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.32% (+113 points), S&P futures are UP +0.33% (+15 points) and NASDAQ futures are UP +0.29% (+44 points)
Stock futures are up Tuesday pre-open waiting for consumer confidence data release
European stocks were trading positive
Asia-Pacific stocks were also up and positive although Mainland China shed gains
Henry’omics:
Last night, the Dow rose 94.65 points or 0.27%, the S&P 500 climbed 32.46 points or 0.71%, while the Nasdaq gained 185.60 or 1.31%.
Economic Date Docket: consumer confidence and home price data
The 10-year U.S. Treasury yield eased to 2.47% Monday, holding at its highest level since May 2019 following Friday's surge. U.S. oil prices dived more than 9% Monday, as West Texas Intermediate crude traded below $104 a barrel. <IBD>
Inflation worries are also mounting …
Investors got some relief on Monday as the CBOE Volatility Index (^VIX), which measures volatility and serves as a gauge of market sentiment, dipped. Wall Street's "fear index," better known as the VIX, settled below 20 for the first time since January after hovering at elevated levels in recent weeks. <yahoo finance>
RegMed Investors’ (RMi) closing bell: “slippage following the fears of risk headlines as subplots remain elevated with geo-political and Fed actions facilitated by capricious sentiment” … https://www.regmedinvestors.com/articles/12363
Ebb and flow –
· March – 11 negative and 9 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (VSTM & BCLI) 33 total to date
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
BUY:
Caribou Biosciences (CRBU) closed up +$0.12 with a positive +$0.16 or +1.71% PRE-OPEN INDICATION.
CRISP Therapeutics (CRSP) closed up +$0.69 with a positive +$0.17 or +0.27% pre-open indication.
SELL:
Agenus (AGEN) closed down -$0.03 after Friday’s -$0.09 with a negative -$0.05 or -1.87% pre-open indication.
BioLife Solutions (BLFS) closed up +$0.30 after Friday’s -$1.116 with a negative -$0.10 or +0.47% pre-open indication.
Pimp/Pump and Promote:
Biostage (OTCQB: BSTG) closed up +$0.26 to $5.00 with 13,012 shares traded after Friday’s +$0.44 with 1,978 shares traded, Thursday’s flat with 34 shares traded, Wednesday with 4 shares traded and last Tuesday’s down -$0.17 with 202 shares traded. WHY BUY these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
The BOTTOM LINE: Cell and gene therapy equities have oscillated between gains and losses for the past.
Monday closed negative, Friday closed negative, Thursday closed positive, Wednesday closed negative, Tuesday closed positive and last Monday closed negative – I an NOT feeling the upside “jollies”.
Reiterating, “Resistance, sentiment algorithms and electronic trading numbing the share pricing as BOREDOM inhabits the sector.
Hold-on (to the railing) as a portfolio weather these volatile sessions is an ordinary practice.
Again, I reiterate, “I’m never totally wrong but, not always wholly right after Monday, Tuesday, Wednesday, Thursday’s closes and last Friday’s week end.
There is no clear trend ….
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
